Moderna Inc
NASDAQ:MRNA
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
36.85
166.61
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Moderna Inc
Moderna Inc
Cash Equivalents
Moderna Inc
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Moderna Inc
NASDAQ:MRNA
|
Cash Equivalents
$1.6B
|
CAGR 3-Years
-33%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash Equivalents
$7.3B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-1%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash Equivalents
$5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash Equivalents
$9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
9%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash Equivalents
$6.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash Equivalents
$2B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
Moderna Inc
Glance View
Moderna Inc. emerged as a game-changer in the biotechnology sector, leveraging its groundbreaking mRNA technology to develop innovative vaccines and therapies. Founded in 2010, the company initially focused on utilizing messenger RNA to instruct cells to produce proteins that could fight off diseases. This vision became a reality when Moderna's COVID-19 vaccine received emergency use authorization in late 2020, marking a pivotal moment not only for public health but for the firm itself. As a player in the rapidly evolving pharmaceutical landscape, Moderna's success has spurred substantial recognition and investment, showcasing its potential to address not just infectious diseases but also other serious health conditions such as cancer and rare genetic disorders. From an investment perspective, Moderna embodies a blend of growth potential and cutting-edge technology, highlighted by its strong pipeline of mRNA-based therapeutics. With significant revenue generated from its COVID-19 vaccine, the company has been able to reinvest in research and development, enhancing its capabilities to tackle various diseases. Furthermore, as global vaccination efforts continue, Moderna's valuable partnerships with governments and healthcare organizations position it well for sustainable growth. Investors should consider the company's innovative approach, robust financial performance, and the potential for continued advancements in mRNA technology as key factors that could drive long-term value in an increasingly competitive biotech arena.
See Also
What is Moderna Inc's Cash Equivalents?
Cash Equivalents
1.6B
USD
Based on the financial report for Sep 30, 2024, Moderna Inc's Cash Equivalents amounts to 1.6B USD.
What is Moderna Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
57%
Over the last year, the Cash Equivalents growth was -44%. The average annual Cash Equivalents growth rates for Moderna Inc have been -33% over the past three years , 57% over the past five years .
You don't have any saved screeners yet
